DB17786InvestigationalProtein Based Therapies
Pagibaximab: Overview.
- Also known as
- IMMUNOGLOBULIN G1, ANTI (STAPHYLOCOCCUS EPIDERMIDIS LIPOTEICHOIC ACID) (HUMAN MOUSE MONOCLONAL HU96 110 HEAVY CHAIN), DISULFIDE WITH HUMAN MOUSE MONOCLONAL HU96 110 .KAPPA.-CHAIN, DIMER · Immunoglobulin G1, anti-(Staphylococcus epidermidis lipoteichoic acid) (human-mouse monoclonal heavy chain), disulfide with human-mouse monoclonal κ-chain, dimer · IMMUNOGLOBULIN G1, ANTI-(STAPHYLOCOCCUS EPIDERMIDIS LIPOTEICHOIC ACID)(HUMAN-MOUSE MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL .KAPPA.-CHAIN, DIMER
- Code names
- A-110 · BSYX-A 110
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Pagibaximab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account